CASPR - Center for Addiction Science, Policy, and Research

We are funding ground-breaking research and real-world programs, and advancing policy that will drive innovation in addiction medicine. Read this article by Nicholas Reville for the full update of what the CASPR team is up to: https://lnkd.in/g34tpvnF

Caron Center Launches An Innovative Program: Using GLP-1 Meds For Addictive Disorders We are honored to support this groundbreaking program, the Bridge Initiative at Caron Treatment Centers, led by Steven Klein M.D.,Ph.D. The Initiative will add GLP-1RA therapy into residential treatment programs for individuals in early recovery. In Dr Klein's words: "We can no longer remain passive as barriers imposed by pharmaceutical companies and insurance providers obstruct access to effective treatment for substance use disorders. The growing body of evidence supporting the efficacy of GLP-1 receptor agonists in the treatment of addiction underscores the urgency of expanding access to these medications. The Bridge Initiative is committed to promoting equitable access to these life-saving treatments and ensuring their timely delivery to the individuals who need them most. Caron has a distinguished history of integrating cutting-edge scientific innovation with evidence-based recovery principles to deliver truly comprehensive care. With the generous support of CASPR, we are proud to carry this tradition forward—prioritizing patient recovery and advancing the frontiers of addiction treatment. This initiative would not be possible without CASPR’s unwavering support, and we commend their deep commitment to the continued advancement and refinement of addiction care." Caron Treatment Centers have been supporting patients with substance use disorders for nearly 70 years, across facilities nation-wide. Their focus on the whole person informs their treatment approach, which combines proven treatment and innovative approaches across the biological, psychological, and social aspects of addiction.

Caron Center Launches An Innovative Program: Using GLP-1 Meds For Addictive Disorders We are honored to support this groundbreaking program, the Bridge Initiative at Caron Treatment Centers, led by Steven Klein M.D.,Ph.D. The Initiative will add GLP-1RA therapy into residential treatment programs for individuals in early recovery. In Dr Klein's words: "We can no longer remain passive as barriers imposed by pharmaceutical companies and insurance providers obstruct access to effective treatment for substance use disorders. The growing body of evidence supporting the efficacy of GLP-1 receptor agonists in the treatment of addiction underscores the urgency of expanding access to these medications. The Bridge Initiative is committed to promoting equitable access to these life-saving treatments and ensuring their timely delivery to the individuals who need them most. Caron has a distinguished history of integrating cutting-edge scientific innovation with evidence-based recovery principles to deliver truly comprehensive care. With the generous support of CASPR, we are proud to carry this tradition forward—prioritizing patient recovery and advancing the frontiers of addiction treatment. This initiative would not be possible without CASPR’s unwavering support, and we commend their deep commitment to the continued advancement and refinement of addiction care." Caron Treatment Centers have been supporting patients with substance use disorders for nearly 70 years, across facilities nation-wide. Their focus on the whole person informs their treatment approach, which combines proven treatment and innovative approaches across the biological, psychological, and social aspects of addiction.

Honored and excited to support this groundbreaking new program working with GLP-1s for addiction treatment.

CASPR, and our research on GLP-1s for opioid use disorder, got a shout-out in this fascinating conversation between Naval Ravikant and Chris Williamson. They discussed the ideas that will shape the future, and call out GLP-1s to treat addiction. See us at minute 5:30 for Naval's shout-out, but the full conversation is well worth your time. https://lnkd.in/gtz5Nx29

Our co-founder, Nicholas Reville, will be speaking at the Cato Institute tomorrow at 12PM EST on 'The Harm Reduction Promise of GLP-1s' Register at the link below to join virtually, and hear about the transformative potential of GLP-1s in treating substance use disorders, and the policies that could improve affordability and access to those who need them [https://lnkd.in/ea59M7eu]

Did you know medications used for diabetes and obesity might also reduce opioid overdose rates? CASPR - Center for Addiction Science, Policy, and Research and the Philadelphia Research and Education Foundation (PREF) are diving into this possibility at the Corporal Michael J. Crescenz VA Medical Center. Led by Dr. Dave Oslin, this study explores how GLP-1 receptor agonists could transform opioid use disorder (OUD) treatment for veterans. With the U.S. Department of Veterans Affairs comprehensive healthcare system, we're in a unique position to uncover new paths to recovery!

How about some good news to start your day? CASPR's Nicholas Reville spoke to Chris Hayes on his podcast about the research, policy and economics of GLP-1s for addiction, and why we should all be optimistic about the future of treating and curing addiction: https://lnkd.in/de_BzQjG Give the episode a listen wherever you get your podcasts, and let us know what you think!

We are excited to report on lots of great progress at CASPR: - Nicholas Reville has been invited to speak at the CATO Institute on Jan 24th. - We've grown our team to include Lucia Simpson as Strategic Associate - We are working to launch new studies / trials on GLP-1s for addiction with several partners, including the U.S. Department of Veterans Affairs. We’ll be posting more about specific trials soon. For more details, read our full post: